PAR-1 and thrombin: The ties that bind the microenvironment to melanoma metastasis

Cancer Research

Volumn 71, Issue 21, 2011, Pages 6561-6566

  Zigler, Maya ^a   Kamiya, Takafumi ^a   Brantley, Emily C ^a   Villares, Gabriel J ^a   Bar Eli, Menashe ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CONNEXIN 43; FIBRIN; INTERSTITIAL COLLAGENASE; MASPIN; MITOGEN ACTIVATED PROTEIN KINASE 1; PROTEIN KINASE B; PROTEINASE ACTIVATED RECEPTOR 1; PROTEINASE ACTIVATED RECEPTOR 1 INHIBITOR; THROMBIN; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; UNCLASSIFIED DRUG;

BLOOD CLOTTING; CANCER GROWTH; CANCER INVASION; CELL ADHESION; CELL INTERACTION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; COLON CANCER; CONNEXIN 43 GENE; DRUG TARGETING; ENDOTHELIUM CELL; FIBRIN DEPOSITION; FIBRINOLYSIS; GENE; GENE EXPRESSION; HUMAN; INTRACELLULAR SIGNALING; LUNG METASTASIS; MASPIN GENE; MELANOMA; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINASE ACTIVATED RECEPTOR 1 GENE; REVIEW; STROMA CELL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; TRANSENDOTHELIAL AND TRANSEPITHELIAL MIGRATION; TUMOR CELL; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD COAGULATION; CELL ADHESION; CELL MOVEMENT; DISEASE PROGRESSION; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; NEOPLASTIC CELLS, CIRCULATING; PHENOTYPE; RECEPTOR, PAR-1; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STROMAL CELLS; THROMBIN; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80155171682     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-1432     Document Type: Review

References (37)

1. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil'hypothesis revisited. Nat Rev Cancer 2003;3:453-8. (Pubitemid 37328849)
2. Villanueva J, Herlyn M. Melanoma and the tumor microenvironment. Curr Oncol Rep 2008;10:439-46.
3. Milsom C, Yu J, May L, Meehan B, Magnus N, Al-Nedawi K, et al. The role of tumor-and host-related tissue factor pools in oncogene-driven tumor progression. Thromb Res 2007;120[Suppl 2]:S82-91. (Pubitemid 350101776)
4. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000;407:258-64.
5. Villares GJ, Zigler M, Bar-Eli M. The emerging role of the thrombin receptor (PAR-1) in melanoma metastasis-a possible therapeutic target. Oncotarget 2011;2:8-17.
6. Hu L, Roth JM, Brooks P, Luty J, Karpatkin S. Thrombin up-regulates cathepsin D which enhances angiogenesis, growth, and metastasis. Cancer Res 2008;68:4666-73.
7. Nierodzik ML, Chen K, Takeshita K, Li JJ, Huang YQ, Feng XS, et al. Protease-activated receptor 1 (PAR-1) is required and rate-limiting for thrombin-enhanced experimental pulmonary metastasis. Blood 1998;92:3694-700. (Pubitemid 28525196)
8. Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell 2006;10:355-62. (Pubitemid 44693468)
9. Rickles FR, Patierno S, Fernandez PM. Tissue factor, thrombin, and cancer. Chest 2003;124[Suppl]:58S-68S. (Pubitemid 37128437)
10. Massi D, Naldini A, Ardinghi C, Carraro F, Franchi A, Paglierani M, et al. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma. Hum Pathol 2005;36:676-85. (Pubitemid 40922575)
11. Villares GJ, Zigler M, Wang H, Melnikova VO, Wu H, Friedman R, et al. Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res 2008;68:9078-86.
12. Melnikova VO, Balasubramanian K, Villares GJ, Dobroff AS, Zigler M, Wang H, et al. Crosstalk between protease-activated receptor 1 and platelet-activating factor receptor regulates melanoma cell adhesion molecule (MCAM/MUC18) expression and melanoma metastasis. J Biol Chem 2009;284:28845-55.
13. Villares GJ, Dobroff AS, Wang H, Zigler M, Melnikova VO, Huang L, et al. Overexpression of protease-activated receptor-1 contributes to melanoma metastasis via regulation of connexin 43. Cancer Res 2009;69:6730-7.
14. Villares GJ, Zigler M, Dobroff AS, Wang H, Song R, Melnikova VO, et al. Protease activated receptor-1 inhibits the Maspin tumor-suppressor gene to determine the melanoma metastatic phenotype. Proc Natl Acad Sci U S A 2011;108:626-31.
15. Shi X, Gangadharan B, Brass LF, Ruf W, Mueller BM. Proteaseactivated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. Mol Cancer Res 2004;2:395-402. (Pubitemid 39031073)
16. Salah Z, Maoz M, Pokroy E, Lotem M, Bar-Shavit R, Uziely B. Protease-activated receptor-1 (hPar1), a survival factor eliciting tumor progression. Mol Cancer Res 2007;5:229-40. (Pubitemid 46577967)
17. Blackburn JS, Liu I, Coon CI, Brinckerhoff CE. A matrix metalloproteinase- 1/protease activated receptor-1 signaling axis promotes melanoma invasion and metastasis. Oncogene 2009;28:4237-48.
18. Arora P, Ricks TK, Trejo J. Protease-activated receptor signalling, endocytic sorting and dysregulation in cancer. J Cell Sci 2007;120: 921-8. (Pubitemid 46638507)
19. Booden MA, Eckert LB, Der CJ, Trejo J. Persistent signaling by dysregulated thrombin receptor trafficking promotes breast carcinoma cell invasion. Mol Cell Biol 2004;24:1990-9. (Pubitemid 38248939)
20. García-López MT, Gutiérrez-Rodríguez M, Herranz R. Thrombin-activated receptors: promising targets for cancer therapy? Curr Med Chem 2010;17:109-28.
21. Yang E, Boire A, Agarwal A, Nguyen N, O'Callaghan K, Tu P, et al. Blockade of PAR1 signaling with cell-penetrating pepducins inhibits Akt survival pathways in breast cancer cells and suppresses tumor survival and metastasis. Cancer Res 2009;69:6223-31.
22. Darmoul D, Gratio V, Devaud H, Lehy T, Laburthe M. Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. Am J Pathol 2003;162:1503-13. (Pubitemid 36512832)
23. Chay CH, Cooper CR, Gendernalik JD, Dhanasekaran SM, Chinnaiyan AM,RubinMA,et al.Afunctional thrombin receptor (PAR1)isexpressed on bone-derived prostate cancer cell lines. Urology 2002;60:760-5. (Pubitemid 35300332)
24. Wilson SR, Gallagher S, Warpeha K, Hawthorne SJ. Amplification of MMP-2 and MMP-9 production by prostate cancer cell lines via activation of protease-activated receptors. Prostate 2004;60:168-74. (Pubitemid 38758582)
25. D'Andrea MR, Derian CK, Santulli RJ, Andrade-Gordon P. Differential expression of protease-activated receptors-1 and -2 in stromal fibroblasts of normal, benign, and malignant human tissues. Am J Pathol 2001;158:2031-41. (Pubitemid 32545189)
26. Tarzami ST, Wang G, Li W, Green L, Singh JP. Thrombin and PAR-1 stimulate differentiation of bone marrow-derived endothelial progenitor cells. J Thromb Haemost 2006;4:656-63.
27. Sen P, Gopalakrishnan R, Kothari H, Keshava S, Clark CA, Esmon CT, et al. Factor VIIa bound to endothelial cell protein C receptor activates protease activated receptor-1 and mediates cell signaling and barrier protection. Blood 2011;117:3199-208.
28. Cheng T, Liu D, Griffin JH, Fernández JA, Castellino F, Rosen ED, et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003;9: 338-42. (Pubitemid 36362790)
29. Camerer E, Qazi AA, Duong DN, Cornelissen I, Advincula R, Coughlin SR. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood 2004;104:397-401. (Pubitemid 38900020)
30. Karpatkin S, Pearlstein E, Ambrogio C, Coller BS. Role of adhesive proteins in platelet tumor interaction in vitro and metastasis formation in vivo. J Clin Invest 1988;81:1012-9.
31. Trivedi V, Boire A, Tchernychev B, Kaneider NC, Leger AJ, O'Callaghan K, et al. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell 2009;137: 332-43.
32. Chalmers CJ, Balmanno K, Hadfield K, Ley R, Cook SJ. Thrombin inhibits Bim (Bcl-2-interacting mediator of cell death) expression and prevents serum-withdrawal-induced apoptosis via protease-activated receptor 1. Biochem J 2003;375:99-109. (Pubitemid 37255385)
33. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010;363:809-19.
34. Macaulay TE, Allen C, Ziada KM. Thrombin receptor antagonism-the potential of antiplatelet medication SCH 530348. Expert Opin Pharmacother 2010;11:1015-22.
35. Silini A, Ghilardi C, Ardinghi C, Bernasconi S, Oliva P, Carraro F, et al. Protease-activated receptor-1 (PAR-1) promotes the motility of human melanomas and is associated to their metastatic phenotype. Clin Exp Metastasis 2010;27:43-53.
36. Sparsa A, Durox H, Doffoel-Hantz V, Munyangango EM, Bédane C, Cendras J, et al. High prevalence and risk factors of thromboembolism in stage IV melanoma. J Eur Acad Dermatol Venereol 2011;25:340-4.
37. Tsopanoglou NE, Maragoudakis ME. Thrombin's central role in angiogenesis and pathophysiological processes. Eur Cytokine Netw 2009;20:171-9.